Merck KGaA (LON:0O14)
London
· Delayed Price · Currency is GBP · Price in EUR 120.65
+0.75 (0.63%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Process Solutions Revenue | 3.75B | 3.52B |
Log In |
Log In |
Log In | Upgrade
|
| Life Science Services Revenue | 691.80M | 721.80M |
Log In |
Log In |
Log In | Upgrade
|
| Science & Lab Solutions Revenue | 4.59B | 4.67B |
Log In |
Log In |
Log In | Upgrade
|
| Life Science Revenue | 9.03B | 8.92B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 1.98B | 2.01B |
Log In |
Log In |
Log In | Upgrade
|
| Neurology & Immunology Revenue | 1.67B | 1.69B |
Log In |
Log In |
Log In | Upgrade
|
| Fertility Revenue | 1.47B | 1.53B |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular, Metabolism and Endocrinology Revenue | 3.03B | 2.95B |
Log In |
Log In |
Log In | Upgrade
|
| Other Healthcare Revenue | 315.50M | 280.50M |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Revenue | 8.56B | 8.45B |
Log In |
Log In |
Log In | Upgrade
|
| Display Solutions Revenue | 770.20M | 748.30M |
Log In |
Log In |
Log In | Upgrade
|
| Surface Solutions Revenue | 342.00M | 406.50M |
Log In |
Log In |
Log In | Upgrade
|
| Semiconductor Solutions Revenue | 2.57B | 2.63B |
Log In |
Log In |
Log In | Upgrade
|
| Electronics Revenue | 3.69B | 3.79B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Europe Revenue | 6.39B | 6.17B |
Log In |
Log In |
Log In | Upgrade
|
| North America Revenue | 5.60B | 5.71B |
Log In |
Log In |
Log In | Upgrade
|
| Asia Pacific Revenue | 7.05B | 7.02B |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Revenue | 1.43B | 1.48B |
Log In |
Log In |
Log In | Upgrade
|
| Middle East & Africa Revenue | 795.30M | 781.20M |
Log In |
Log In |
Log In | Upgrade
|
EBITDA
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Life Science EBITDA | 2.61B | 2.59B |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare EBITDA | 3.13B | 2.99B |
Log In |
Log In |
Log In | Upgrade
|
| Electronics EBITDA | 856.40M | 969.60M |
Log In |
Log In |
Log In | Upgrade
|
| Corporate/Others EBITDA | -434.20M | -481.80M |
Log In |
Log In |
Log In | Upgrade
|